Key result
An intraoperative remifentanil dose of ≥4.0 mg significantly increased the risk of postoperative ileus (OR 5.142) compared to lower doses in patients undergoing elective colorectal surgery.
Why the study?
Does an intraoperative remifentanil dose of ≥4.0 mg increase the risk of postoperative ileus in patients undergoing elective colorectal surgery?
Observational (n=114)
No
Does an intraoperative remifentanil dose of ≥4.0 mg increase the risk of postoperative ileus in patients undergoing elective colorectal surgery?
An intraoperative remifentanil dose of ≥4.0 mg is an independent risk factor for postoperative ileus after elective laparoscopic colorectal surgery, with the risk increasing when coexisting with male sex.
May support limiting intraoperative remifentanil in colorectal surgery; hypothesis-generating and requires prospective confirmation.
Purpose: The aim of this study was to determine whether various patient characteristics and perioperative clinical interventions might be correlated with the incidence of postoperative ileus (POI). Methods: We prospectively investigated 114 patients who were scheduled to undergo elective colorectal surgery. The associations of patient characteristics and clinical interventions with POI were examined statistically. We also included preoperative stress as a possible predictor of POI. Results: A total of 11 (9.7%) patients developed POI. Univariate analyses showed that an intraoperative remifentanil dose of ≥4.0mg was significantly associated with the occurrence of POI. Although a multivariate analysis showed that only an intraoperative remifentanil dose of ≥4.0 mg was statistically correlated with the occurrence of POI (p=0.0375), the risk for POI increased significantly with the number of other predictive factors present: a male sex, and an intraoperative remifentanil dose of ≥4.0 mg. A correlation between preoperative stress and the incidence of POI was not found. Conclusions: Our study suggests that an intraoperative remifentanil dose of ≥4.0 mg is a risk factor for POI and that the risk increases when it coexists with a male sex. Further study is needed to clarify the correlations among a male sex, intraoperative remifentanil use, and the incidence of POI.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (2017) conducted an observational in Postoperative ileus (n=114). Intraoperative remifentanil dose ≥4.0 mg vs. Intraoperative remifentanil dose <4.0 mg was evaluated on Incidence of postoperative ileus (POI) (OR 5.142, 95% CI 1.100-24.049, p=0.0375). An intraoperative remifentanil dose of ≥4.0 mg significantly increased the risk of postoperative ileus (OR 5.142) compared to lower doses in patients undergoing elective colorectal surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: